This study will provide continued access to Gefitinib (Iressa) to United States patients who are currently receiving and benefiting or have previously benefited from treatment with Gefitinib under the IRE SSA™ Access Program (held under NDA 21-399) as well as patients who are currently benefiting or have benefited from treatment with Gefitinib through a clinical trial that was IRB approved prior to 17 June 2005 under the current IND (54,576) following closure of the current NDA (21-399).
An Open Label, Multi-center, IRESSA™ Clinical Access Program of Gefitinib 250 mg (IRESSA™ ) for the Continued Treatment of Patients in the United States Currently Benefiting or Who Have Benefited From Treatment with Gefitinib
004-11Principal Investigator: Conducted at:
Orange Coast Medical CenterCurrently enrolling additional patients:
18 years & up